Spots Global Cancer Trial Database for aggressive lymphoma
Every month we try and update this database with for aggressive lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma | NCT00689169 | Lymphoma, Large... | ZBEAM (Zevalin,... ASCT Rituximab | 18 Years - 65 Years | Lymphoma Study Association | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| A Study Of The Selective PKC-β Inhibitor MS- 553 | NCT03492125 | Chronic Lymphoc... Small Lymphocyt... Aggressive Lymp... | MS-553 MS-553 acalabrutinib venetoclax Rituximab obinutuzumab | 18 Years - | MingSight Pharmaceuticals, Inc | |
| STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma | NCT01653067 | Diffuse Large B... | Rituximab, Tems... | 18 Years - | University Hospital Heidelberg | |
| Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma | NCT01686321 | Aggressive Lymp... | Bendamustine an... | 60 Years - | University of Göttingen | |
| Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | NCT02290951 | Non-Hodgkin Lym... Chronic Lymphoc... | Odronextamab mu... Odronextamab mu... | 18 Years - | Regeneron Pharmaceuticals | |
| Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL | NCT01562977 | Aggressive Lymp... Diffuse Large B... Mantle Cell Lym... | Rituximab, Gemc... | 18 Years - | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | NCT02290951 | Non-Hodgkin Lym... Chronic Lymphoc... | Odronextamab mu... Odronextamab mu... | 18 Years - | Regeneron Pharmaceuticals | |
| A Study Of The Selective PKC-β Inhibitor MS- 553 | NCT03492125 | Chronic Lymphoc... Small Lymphocyt... Aggressive Lymp... | MS-553 MS-553 acalabrutinib venetoclax Rituximab obinutuzumab | 18 Years - | MingSight Pharmaceuticals, Inc | |
| High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas | NCT01148173 | Lymphoma, Non-H... | Combined system... | 18 Years - 65 Years | Charite University, Berlin, Germany | |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04806035 | CLL SLL Richter's Trans... Indolent Lympho... Follicular Lymp... Marginal Zone L... Aggressive Lymp... DLBCL Mediastinal Lar... MCL | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Italian Multicenter Retrospective Observational Study on Transformed Lymphomas | NCT02927756 | Non-Hodgkin Lym... | 18 Years - | Azienda Ospedaliera Città della Salute e della Scienza di Torino |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
